Prognostic value of the albumin–globulin ratio and albumin–globulin score in patients with multiple myeloma

Ying Cai¹, Yu Zhao¹, Qiuxin Dai¹, Maozhong Xu¹, Xin Xu¹ and Wenkai Xia²,³

Abstract

Objective: The albumin–globulin ratio (AGR) has been identified as a promising prognostic predictor of mortality in patients with hematological malignancies. This study investigated the prognostic significance of AGR in patients with multiple myeloma.

Methods: Two hundred patients diagnosed with multiple myeloma from January 2010 to October 2018 were retrospectively analyzed and followed up until December 2019. Kaplan–Meier curves and multivariate Cox regression analysis were applied to detect the prognostic value of AGR.

Results: The median follow-up period was 36 months. The optimal cutoff of AGR was 1.16 according to receiver operating characteristic curve analysis. High AGR was significantly correlated with better overall survival (OS) and progression-free survival (PFS). Multivariate analysis revealed that low AGR was an independent prognostic factor for worse OS (hazard ratio [HR] = 1.82, 95% confidence interval [CI] = 1.15–2.94) and PFS (HR = 1.53, 95% CI = 1.09–2.17).

Conclusions: AGR may represent a potential prognostic biomarker in patients with multiple myeloma.

Mini Abstract: We demonstrated that high AGR was associated with a favorable overall survival and progression-free survival in patients with multiple myeloma.

¹Department of Hematology, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu, China
²Department of Nephrology, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu, China
³Nephrologisches Zentrum, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ludwig-Maximilians-University Munich, Munich, Germany

Corresponding author:
Wenkai Xia, Department of Nephrology, The Affiliated Jiangyin Hospital of Southeast University Medical College, 3 Yinrui Road, Jiangyin, Jiangsu 214400, China.
Email: xiawenkai23@163.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Multiple myeloma (MM), which is characterized by a measurable immunoglobulin (Ig) peak in plasma or urine caused by the abnormal proliferation of atypical plasma cells in bone marrow, is a major hematological malignancy globally that is associated with high morbidity and mortality. Despite substantial advances in the diagnosis and treatment (chemotherapy and stem cell therapy) of MM, long-term survival remains unsatisfactory owing to ineffective drug treatment, disease-related complications, and local relapse. At present, a number of prognostic models of clinical characteristics have considerably increased the available tools for screening patients with advanced disease and poor prognoses, including the Durie–Salmon Staging System, International Staging System (ISS), and Revised International Staging System (RISS). However, patients within similar prognostic groups display heterogeneous clinical outcomes. Therefore, it is imperative to apply critical MM markers together with traditional clinical parameters to improve the prediction of prognosis and survival.

It is accepted that malnutrition and inflammation are highly prevalent and related to the prognosis of patients with cancers. In general, serum albumin is used to reflect malnutrition, whereas serum globulin serves as an indicator of chronic inflammation. However, emerging evidence illustrated that hypoalbuminemia may represent a reliable indicator of an enhanced cancer-related inflammatory response, which is mainly associated with cytokine-induced impairment of albumin synthesis and excessive albumin degradation. Recent studies identified the albumin–globulin ratio (AGR) as a valuable marker for predicting the survival of patients with different types of lymphoma and other diseases such as chronic kidney disease and chronic obstructive pulmonary disease. However, there is a lack of evidence regarding the predictive role of AGR and the albumin–globulin score (AGS) for mortality in patients with MM. The purpose of the current study was to evaluate the influence of AGR and AGS on clinical prognosis in patients with MM.

Patients and methods

Participants

The retrospective study enrolled patients with newly diagnosed MM between January 2010 and October 2018 in The Affiliated Jiangyin Hospital, School of Medicine, Southeast University. The diagnosis of MM was based on the criteria published by the International Myeloma Working Group. The staging of MM was determined using the Durie–Salmon Staging System, ISS, and RISS. The study was approved by the Medical Ethics Committee of The Affiliated Jiangyin Hospital of Southeast University Medical College. The need for informed consent
was waived because of the retrospective nature of this study.

**Clinical and laboratory data collection**

All blood samples were collected before treatment to measure the following variables: hemoglobin; mean corpuscular hemoglobin; mean corpuscular hemoglobin concentration (MCHC); mean corpuscular volume; red blood cell distribution width; white blood cell, neutrophil, and lymphocyte counts; and albumin, globulin, β2-microglobulin, and lactate dehydrogenase (LDH) levels. AGR was determined using the following formula: $\text{AGR} = \frac{\text{albumin}}{\left(\frac{\text{total proteins}}{\text{albumin}}\right)}$. Patients with MM and low albumin levels ($\leq 35$ g/L) and high globulin levels ($>35$ g/L) were given an AGS of 2, those with only one abnormality were given an AGS of 1, and those with neither abnormality were given an AGS of 0. AGS of 1–2 was characterized as high, and AGS of 0 was characterized as low.

Patients with MM were routinely followed up every 3 months for the first 2 years and then every 6 months up to the fifth year. Overall survival (OS) was calculated from diagnosis to death. The date of last follow-up was applied for withdrawn patients. Progression-free survival (PFS) was calculated from diagnosis to disease progression or relapse or until the date of last follow-up.

**Statistical analysis**

Receiver operating characteristic (ROC) curves were applied to evaluate the sensitivity and specificity for OS and PFS, and the largest Youden’s index was estimated to determine the optimal cutoff points for AGR.\(^{11}\) Comparisons of continuous variables were performed using the Mann–Whitney U test or Kruskal–Wallis test. Comparisons of categorical variables were performed using the chi-squared test or Fisher’s exact test. Survival rates in terms of OS and PFS were analyzed using the Kaplan–Meier method and log-rank test. The significant predictors of OS and PFS were evaluated by multivariate analysis using Cox’s proportional hazards model. Nomograms for OS and PFS were generated using R 3.0.3 software (Institute for Statistics and Mathematics, Vienna, Austria), and the predictive accuracy was evaluated using Harrell’s concordance index. All statistical analysis was performed using SPSS 20.0 software (IBM, Armonk, NY, USA).

**Results**

**Patient characteristics**

The clinicopathologic characteristics of all patients with MM stratified by AGS and AGR are described in Table 1. The study included 200 patients with MM, including 82 (41.0%) males and 118 (59%) females with a median age of 66 years (range, 29–88). The most prevalent MM type was IgG (49.4%). Twelve (6%) patients had bone marrow infiltration. The median follow-up periods for OS and PFS were 34 and 22 months, respectively. In the final follow-up, relapse or disease progression was identified in 183 (91.5%) patients, and 130 (65.0%) patients had died.

**Optimal thresholds for AGR**

The optimal cutoff for AGR was determined using ROC curve analysis. The area under the curve for AGR was 0.678 (95% confidence interval [CI] = 0.600–0.757, $P < 0.001$). The optimal cutoff based on OS was determined to be 1.16 for AGR via ROC curve analysis. Subsequently, patients were divided into two groups according to the optimal cutoff.
Table 1. Baseline patient characteristics according to AGS and AGR at diagnosis.

| Characteristics | Cases (n = 200) | AGS = 0 (n = 26) | AGS = 1–2 (n = 174) | P | AGR ≤ 1.16 (n = 145) | AGR > 1.16 (n = 55) | P |
|-----------------|-----------------|------------------|---------------------|---|---------------------|---------------------|---|
| Age, years      | 64 ± 8          | 66 ± 10          | 0.360               |   | 65 ± 10             | 64 ± 8              | 0.237 |
| Gender, n (%)   |                 |                  |                     |   |                     |                     |   |
| Male            | 12 (46.2)       | 70 (40.2)        | 0.567               |   | 59 (40.7)           | 23 (41.8)           | 0.885 |
| Hb (g/L)        | 96.19 ± 25.70   | 89.12 ± 23.27    | 0.155               |   | 87.45 ± 22.61       | 96.84 ± 25.15       | 0.012 |
| RBCs (× 10¹²/L) | 3.13 ± 0.90     | 2.92 ± 0.76      | 0.211               |   | 2.86 ± 0.74         | 3.16 ± 0.86         | 0.017 |
| MCV (fL)        | 93.59 ± 5.26    | 93.64 ± 5.93     | 0.967               |   | 93.97 ± 5.67        | 92.73 ± 6.23        | 0.201 |
| MCH (pg)        | 31.05 ± 1.66    | 30.64 ± 2.07     | 0.331               |   | 30.62 ± 2.07        | 30.89 ± 1.90        | 0.383 |
| MCHC (g/L)      | 332.0 (324.3–341.5) | 327.5 (320.0–336.0) | 0.125               |   | 327.0 (319.0–333.0) | 332.0 (326.0–343.0) | 0.003 |
| RDW (%)         | 13.40 (12.85–14.13) | 14.40 (13.50–16.13) | 0.001               |   | 14.60 (13.60–16.75) | 13.50 (13.10–14.30) | <0.001 |
| WBCs (× 10⁹/L)  | 5.21 (4.40–6.94) | 4.52 (3.48–6.21) | 0.080               |   | 4.43 (3.46–6.19)    | 5.04 (3.67–7.04)    | 0.128 |
| Platelets (× 10⁹/L) | 193.0 (109.5–232.5) | 147.0 (106.0–184.5) | 0.113               |   | 147.0 (109.5–196.0) | 158.0 (102.0–211.0) | 0.520 |
| Albumin (g/L)   | 40.99 ± 3.87    | 33.46 ± 6.23     | <0.001              |   | 32.19 ± 5.47        | 40.37 ± 5.10        | <0.001 |
| Globulin (g/L)  | 24.80 (22.25–27.60) | 56.90 (35.90–73.90) | <0.001              |   | 63.90 (46.55–77.45) | 22.3 (19.10–27.20)  | <0.001 |
| Calcium (mmol/L)| 2.29 (2.19–2.54) | 2.22 (2.06–2.37) | 0.084               |   | 2.22 (2.06–2.35)    | 2.26 (2.07–2.52)    | 0.147 |
| LDH (IU/L)      | 223.7 (159.1–293.3) | 146.5 (117.7–199.3) | <0.001              |   | 142.7 (113.1–190.5) | 199.2 (152.0–253.5) | <0.001 |
| Urea (mmol/L)   | 8.10 (6.45–12.36) | 6.61 (4.86–9.66) | 0.025               |   | 6.50 (4.83–8.46)    | 8.29 (5.70–13.80)   | 0.003 |
| Creatine (mmol/L) | 123.0 (77.2–425.3) | 90.3 (66.9–158.7) | 0.026               |   | 84.50 (64.7–139.45) | 122.8 (81.8–373.0)  | <0.001 |
| j2-microglobulin (mg/L) | 4.60 (3.16–7.65) | 6.96 (3.68–16.67) | 0.067               |   | 6.10 (3.60–14.97)   | 4.32 (3.14–7.18)    | 0.015 |
| IgG, n (%)      | 0 (0)           | 86 (49.4)        | 84 (57.9)           | 2 (3.6) |
| IgA             | 3 (11.5)        | 52 (29.9)        | 49 (33.8)           | 6 (10.9) |
| IgM             | 0 (0)           | 1 (0.6)          | 1 (0.7)             | 0 (0) |
| Light chain (L) | 18 (69.2)       | 24 (13.8)        | 8 (5.5)             | 34 (61.9) |
| Light chain (K) | 4 (15.5)        | 8 (4.6)          | 1 (0.7)             | 11 (20) |
| IgD             | 1 (3.8)         | 1 (0.6)          | 1 (0.7)             | 1 (1.8) |
| Other           | 0 (0)           | 2 (1.1)          | 1 (0.7)             | 1 (1.8) |

(continued)
Table 1. Continued.

| Characteristics                        | Cases (n = 200) | AGS = 0 (n = 26) | AGS = 1–2 (n = 174) | P     | AGR ≤ 1.16 (n = 145) | AGR > 1.16 (n = 55) | P     |
|----------------------------------------|----------------|-----------------|---------------------|-------|---------------------|---------------------|-------|
| Bone marrow infiltration, n (%)        |                |                 |                     |       |                     |                     |       |
| ISS Stage, n (%)                       |                |                 |                     |       |                     |                     |       |
| I                                      | 5 (19.2)       | 16 (9.2)        | 12 (8.3)            | 0.038 | 9 (6.2)             | 3 (5.5)             | 0.841 |
| II                                     | 6 (9.1)        | 84 (48.3)       | 76 (52.4)           |       | 14 (25.5)           |                     |       |
| III                                    | 15 (57.7)      | 74 (42.5)       | 57 (39.3)           |       | 32 (58.2)           |                     |       |
| DS stage, n (%)                        |                |                 |                     |       |                     |                     |       |
| I                                      | 4 (15.4)       | 10 (5.7)        | 6 (4.2)             | 0.140 | 8 (14.5)            |                     | 0.023 |
| II                                     | 8 (30.8)       | 45 (25.9)       | 37 (25.5)           |       | 16 (29.1)           |                     |       |
| III                                    | 14 (53.8)      | 119 (68.4)      | 102 (70.3)          |       | 31 (56.4)           |                     |       |
| RISS stage, n (%)                      |                |                 |                     |       |                     |                     |       |
| I                                      | 5 (19.2)       | 13 (7.5)        | 9 (6.2)             | 0.009 | 9 (16.4)            |                     | 0.020 |
| II                                     | 11 (42.3)      | 125 (71.8)      | 106 (73.1)          |       | 30 (54.5)           |                     |       |
| III                                    | 10 (38.5)      | 36 (20.7)       | 30 (20.7)           |       | 16 (29.1)           |                     |       |
| Treatment, n (%)                       |                |                 |                     |       |                     |                     |       |
| Chemotherapy                           | 25 (96.2)      | 165 (94.8)      | 140 (96.6)          | 0.609 | 52 (94.5)           |                     | 0.687 |
| Stem cell transplant                   | 1 (3.8)        | 9 (5.2)         | 5 (3.4)             |       | 3 (5.5)             |                     |       |
| Deaths, n (%)                          | 12 (46.2)      | 118 (67.8)      | 108 (74.5)          | 0.031 | 23 (41.8)           | <0.001              |       |

AGR, albumin–globulin ratio; AGS, albumin–globulin score; Hb, hemoglobin; RBCs, red blood cells; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RDW, red blood cell distribution width; WBCs, white blood cells; Ig, immunoglobulin; ISS, International Staging System; DS, Durie–Salmon; RISS, Revised International Staging System.
Correlations of AGS and AGR with clinicopathologic parameters

To study the associations of AGS and AGR with clinicopathologic parameters, comparisons between the high and low groups for AGS and AGR were performed, as presented in Table 1. AGS and AGR were significantly associated with RDW, albumin, globulin, LDH, creatine, urea, Ig subtype, and MM stage. Moreover, AGR was closely associated with hemoglobin, red blood cell counts, MCHC, and β2-microglobulin.

Association of AGS and AGR with patient outcomes

Kaplan–Meier analysis of OS and PFS was performed to determine the associations of AGS and AGR with clinical prognosis. Our results revealed that high AGS was associated with decreased OS ($P = 0.049$, Figure 1). In addition, low AGR was significantly associated with poorer OS ($P < 0.001$, Figure 2) and PFS ($P = 0.005$).

The influence of parameters identified as significant in univariate analysis on OS and PFS was investigated via multivariate analysis. Our results revealed that old age was an independent prognostic indicator of OS (hazard ratio $[HR] = 1.02$, 95% CI = 1.00–1.04, $P = 0.026$, Table 2). More importantly, low AGR was significantly associated with reduced OS (HR = 1.82, 95% CI = 1.15–2.94, $P = 0.011$) and PFS (HR = 1.53, 95% CI = 1.09–2.17, $P = 0.028$). Meanwhile, MCHC (HR = 0.98, 95% CI = 0.97–0.99, $P = 0.031$) was identified as an independent predictor of PFS in patients with MM. Moreover, AGS was not an independent indicator of either OS or PFS.

Discussion

Hypoalbuminemia is reported to be predictive of poor prognosis, and it is prevalent in patients with MM. To the best of our knowledge, this is the first study to demonstrate the prognostic value of AGR in terms of OS and PFS in patients with MM. In our study, we demonstrated that high AGR was associated with favorable OS and PFS among patients with MM.

Serum albumin is generally regarded as a biological marker reflecting the nutritional status and systemic inflammatory response. Hypoalbuminemia is a common clinical feature of MM, and it includes multiple etiologies, such as malnutrition, renal dysfunction, and hepatic impairment. Despite great progress in understanding

Figure 1. Kaplan–Meier curves of overall and progression-free survival according to the albumin–globulin score.
the association of serum albumin with the prognosis of several types of cancer, the influence of serum albumin on the prognosis of MM remains unclear. It has been reported that serum interleukin (IL)-6 levels are negatively correlated with serum albumin levels in patients with MM. IL-6 was observed to be significantly overexpressed in various types of B-cell malignancies including MM, and it has been verified that IL-6 overproduction contributes to B-cell maturation and proliferation. Furthermore, the negative effects of hypoalbuminemia on patient prognosis might be partly attributable to its anti-oxidant function, which may induce cell growth stabilization and DNA replication. Conversely, low serum albumin content may indicate malnutrition, which was found to be associated with poor prognosis. However, a recent study revealed that the increased mortality of hypoalbuminemia was partly attributed to inflammation opposed to malnutrition in patients undergoing peritoneal dialysis. In contrast to albumin, globulin is a primary cortisol-binding protein containing several pro-inflammatory components such as Igs, ILs, and C-reactive protein. In fact, globulin has been widely reported as an independent prognostic indicator for various diseases. Therefore, combination variables such as AGR are considered better prognostic markers than individual markers alone.

AGR has been widely investigated as a potential prognostic factor in solid tumors, including breast cancer, glioblastoma, gastric cancer, and renal cell carcinoma. Recently, several studies found that higher AGR was correlated with reduced all-cause mortality in hematological malignancies, primarily lymphomas. The present study suggested that increased AGR was significantly associated with better OS and PFS in patients with MM, and the optimal AGR cutoff of 1.16 was a superior predictor in terms of HR, which achieved the best sensitivity and specificity. A low AGR could be the consequence of sustained protein loss, such as that associated with proteinuria. Proteinuria results in undernutrition and inflammation, which are associated with poor outcomes in patients with chronic disease, even in the general population. Importantly, patients with MM and a low AGR should be assessed for the presence of a strong inflammatory response, malnourishment, or both. Treatment with nutritional support and anti-inflammatory agents might reduce the risk of mortality in patients with MM. Interestingly, AGR is also a predictor of chronic kidney disease.

Figure 2. Kaplan–Meier curves of overall and progression-free survival according to the albumin–globulin ratio.
Table 2. Univariate and multivariate analysis of prognostic factors of overall and progression-free survival by Cox regression model.

| Variable                      | Overall survival          | Progression-free survival | Bone marrow infiltration (yes) |
|-------------------------------|---------------------------|---------------------------|--------------------------------|
|                               | Univariate analysis       | Multivariate analysis     | Univariate analysis           | Multivariate analysis     |
|                               | HR (95% CI) | P   | HR (95% CI) | P   | HR (95% CI) | P   |
| Age (> 65 years)              | 1.03 (1.01–1.05)          | 0.008                      | 1.02 (1.00–1.04) | **0.026**          | 1.01 (0.99–1.03) | 0.073 |
| Gender (male)                 | 0.95 (0.67–1.35)          | 0.780                      |                              |                              | 0.99 (0.74–1.33) | 0.996 |
| Hb (>9.0)                     | 0.53 (0.37–0.75)          | <0.001                     | 0.53 (0.28–1.01) | 0.054          | 0.91 (0.68–1.21) | 0.513 |
| RBCs (> 3.0)                  | 0.65 (0.46–0.93)          | 0.017                      | 1.28 (0.72–2.29) | 0.398          | 0.91 (0.68–1.22) | 0.914 |
| MCV (> 93.6)                  | 1.28 (0.91–1.81)          | 0.156                      |                              |                              | 1.41 (1.05–1.89) | 0.021 |
| MCH (> 30.7)                  | 0.88 (0.62–1.24)          | 0.464                      |                              |                              | 0.92 (0.69–1.23) | 0.595 |
| MCHC (> 336.8)                | 0.60 (0.38–0.95)          | 0.028                      | 0.71 (0.44–1.14) | 0.158          | 0.64 (0.44–0.91) | 0.014 |
| RDW (> 15.8)                  | 1.45 (0.99–2.12)          | 0.055                      |                              |                              | 0.98 (0.97–0.99) | **0.031** |
| WBCs (> 6.2)                  | 1.02 (0.69–1.52)          | 0.909                      |                              |                              | 1.01 (0.95–1.07) | **0.018** |
| Platelets (> 201.8)           | 0.85 (0.57–1.30)          | 0.480                      |                              |                              | 0.89 (0.63–1.25) | 0.504 |
| Calcium (> 2.4)               | 1.27 (0.85–1.89)          | 0.241                      |                              |                              | 0.91 (0.64–1.29) | 0.604 |
| LDH (> 213.6)                 | 1.01 (0.67–1.52)          | 0.969                      |                              |                              | 1.15 (0.82–1.61) | 0.428 |
| Urea (> 9.9)                  | 1.13 (0.76–1.67)          | 0.556                      |                              |                              | 1.46 (1.03–2.09) | 0.038 |
| Creatine (> 170.4)            | 1.18 (0.80–1.75)          | 0.408                      |                              |                              | 1.47 (1.03–2.09) | 0.035 |
| If/2-microglobulin > 8.4      | 1.41 (0.96–2.07)          | 0.079                      |                              |                              | 0.82 (0.58–1.16) | 0.251 |
| lg                            | I                          | I                          | I                             | I                             | I                             | I |
| IgG                           | 1.70 (0.24–12.28)         | 0.598                      | 3.91 (0.54–8.23) | 0.177          |                              |                              |
| IgA                           | 1.35 (0.185–9.81)         | 0.769                      | 3.01 (0.42–7.87) | 0.275          |                              |                              |
| Light chain (L)               | 6.98 (0.43–13.22)         | 0.171                      | 4.89 (0.30–8.98) | 0.263          |                              |                              |
| Light chain (K)               | 1.13 (0.15–8.39)          | 0.903                      | 2.75 (0.38–5.07) | 0.320          |                              |                              |
| IgD                           | 0.42 (0.44–4.04)          | 0.453                      | 1.63 (0.21–2.90) | 0.642          |                              |                              |
| Other                         | 4.75 (0.43–9.78)          | 0.205                      | 8.26 (0.74–17.02) | 0.086          |                              |                              |
| Bone marrow infiltration (yes)| 1.10 (0.54–2.26)          | 0.787                      | 1.31 (0.73–2.35) | 0.369          |                              |                              |

(continued)
| Variable          | Overall survival |                 | Progression-free survival |                 |
|-------------------|------------------|-----------------|---------------------------|-----------------|
|                   | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis |
|                   | HR (95% CI) | P    | HR (95% CI) | P    | HR (95% CI) | P    | HR (95% CI) | P    |
| ISS stage         |                 |                 |                           |                 |
| I                 |                 |                 |                           |                 |
| II                | 1.57 (1.04–2.38) | 0.033 | 1.96 (0.74–5.21) | 0.175 | 1.18 (0.85–1.64) | 0.319 |
| III               | 3.13 (1.27–7.69) | 0.013 | 1.05 (0.63–1.76) | 0.843 | 1.54 (0.85–2.79) | 0.156 |
| DS stage          |                 |                 |                           |                 |
| I                 |                 |                 |                           |                 |
| II                | 1.03 (0.72–1.47) | 0.880 | 0.86 (0.52–1.42) | 0.554 | 0.94 (0.74–1.19) | 0.621 |
| III               | 1.89 (0.97–3.69) | 0.063 | 1.43 (1.05–1.95) | 0.022 |                |      |
| R-ISS stage       |                 |                 |                           |                 |
| I                 |                 |                 |                           |                 |
| II                | 1.23 (0.81–1.89) | 0.336 | 0.71 (0.40–1.27) | 0.251 |                |      |
| III               | 2.09 (0.91–4.81) | 0.082 | 1.02 (0.71–1.45) | 0.920 |                |      |
| Chemotherapy      | 0.33 (0.08–1.33) | 0.118 | 0.91 (0.54–1.56) | 0.738 |                |      |
| Stem cell transplant | 0.65 (0.35–1.19) | 0.165 | 0.46 (0.19–1.12) | 0.085 |                |      |
| AGR (<1.16)       | 1.96 (1.32–2.94) | 0.001 | 1.82 (1.15–2.94) | 0.011 | 1.41 (1.04–1.92) | 0.024 | 1.53 (1.09–2.17) | 0.028 |
| AGS (1–2)         | 1.49 (0.84–2.64) | 0.172 | 1.21 (0.78–1.89) | 0.399 |                |      |

AGR, albumin–globulin ratio; AGS, albumin–globulin score; Hb, hemoglobin; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RDW, red cell distribution width; WBCs, white blood cells; Ig, immunoglobulin; ISS, International Staging System; DS, Durie–Salmon; R-ISS, Revised International Staging System; HR, hazard ratio; CI, confidence interval.
which may be a common manifestation of MM that is associated with an increased risk of all-cause death and cardiovascular disease. However, the applicable cutoff may be different in particular cohorts of patients with MM, and distinct results may be obtained regarding survival comparisons. Furthermore, our study revealed significant differences in OS among patients with MM stratified by AGS and AGR. Unfortunately, we failed to identify AGS as a positive predictor of outcomes for patients with MM in the present study. However, the predictive value of AGS needs further investigation.

Several limitations of the present study should be addressed. First, some CIs in univariate and multivariate Cox regression analysis were wide, which might be attributable to the retrospective, single-center nature of the study and its relatively small cohort of 200 patients, possibly resulting in bias for data collection and analysis. Second, other inflammatory parameters such as cytokines were not examined in our study because they were not routinely measured in our patients. Third, we only investigated the associations of baseline AGR with OS and PFS, and over time, treatment would lead to changes of AGR, which may reflect the dynamic changes of the nutritional and systemic inflammatory status and influence positive or negative clinical outcomes. Another potential limitation was that globulins are heterogeneous fractions that cannot be accurately measured, which may lead to different clinical prognoses.

In conclusion, our study demonstrated that AGR was an independent predictor of OS and PFS in patients with MM. However, further studies are required to identify the underlying mechanism linking inflammatory biomarkers and prognosis in these patients.

Authors’ contributions
WKX and XX developed the protocol; YC, YZ, QXD, and MZX collected the data; YZ and QXD analyzed the data; YC and WKX wrote and edited the manuscript; MZX revised the manuscript. All authors read and approved the final manuscript.

Declaration of conflicting interests
The authors declare that there is no conflict of interest.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

ORCID iD
Wenkai Xia https://orcid.org/0000-0002-3839-3677

References
1. Rajkumar SV. Multiple myeloma: Every year a new standard? *Hematol Oncol* 2019; 37: 62–65.
2. Durie BG and Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. *Cancer* 1975; 36: 842–854.
3. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. *J Clin Oncol* 2005; 23: 3412–3420.
4. Andersson C, Lonnroth C, Moldawer LL, et al. Increased degradation of albumin in cancer is not due to conformational or chemical modifications in the albumin molecule. *J Surg Res* 1990; 49: 23–29.
5. Bi XW, Wang L, Zhang WW, et al. The pretreatment albumin to globulin ratio
predicts survival in patients with natural killer/T-cell lymphoma. PeerJ 2016; 4: e1742.

6. Yue W, Liu B, Gao L, et al. The pretreatment albumin to globulin ratio as a significant predictor in patients with diffuse large B cell lymphoma. Clin Chim Acta 2018; 485: 316–322.

7. Wu PP, Hsieh YP, Kor CT, et al. Association between Albumin-Globulin Ratio and Mortality in Patients with Chronic Kidney Disease. J Clin Med 2019; 8: 1991.

8. Qin J, Qin Y, Wu Y, et al. Application of albumin/globulin ratio in elderly patients with acute exacerbation of chronic obstructive pulmonary disease. J Thorac Dis. 2018; 10: 4923–4930.

9. International Myeloma Working G. Criteria for the classification of monoclonal gammapathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749–757.

10. Rajkumar SV. Updated Diagnostic Criteria and Staging System for Multiple Myeloma. Am Soc Clin Oncol Educ Book 2016; 35: e418–e423.

11. Greiner M, Pfeiffer D and Smith RD. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev Vet Med 2000; 45: 23–41.

12. Kim JE, Yoo C, Lee DH, et al. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma. Ann Hematol 2010; 89: 391–397.

13. Gupta D and Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 2010; 9: 69.

14. Zamora E, Lupon J, Vila J, et al. Estimated glomerular filtration rate and prognosis in heart failure: value of the Modification of Diet in Renal Disease Study-4, chronic kidney disease epidemiology collaboration, and cockroft-gault formulas. J Am Coll Cardiol 2012; 59: 1709–1715.

15. Van Zutphen T, Ciapaite J, Bloks VW, et al. Malnutrition-associated liver steatosis and ATP depletion is caused by peroxisomal and mitochondrial dysfunction. J Hepatol 2016; 65: 1198–1208.

16. Yamashita K, Ushiku H, Katada N, et al. Reduced preoperative serum albumin and absence of peritoneal dissemination may be predictive factors for long-term survival with advanced gastric cancer with positive cytology test. Eur J Surg Oncol 2015; 41: 1324–1332.

17. Bekos C, Polterauer S, Scehacher V, et al. Pre-operative hypoalbuminemia is associated with complication rate and overall survival in patients with vulvar cancer undergoing surgery. Arch Gynecol Obstet 2019; 300: 1015–1022.

18. Hu WH, Eisenstein S, Parry L, et al. Preoperative malnutrition with mild hypoalbuminemia associated with postoperative mortality and morbidity of colorectal cancer: a propensity score matching study. Nutr J 2019; 18: 33.

19. Bataille R, Jourdan M, Zhang XG, et al. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84: 2008–2011.

20. Treon SP and Anderson KC. Interleukin-6 in multiple myeloma and related plasma cell dyscrasias. Curr Opin Hematol 1998; 5: 42–48.

21. Rosean TR, Tompkins VS, Tricot G, et al. Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res 2014; 59: 188–202.

22. Seaton K. Albumin concentration controls cancer. J Natl Med Assoc 2001; 93: 490–493.

23. Jacobsson A, Pihl-Lindgren E and Fridlund B. Malnutrition in patients suffering from chronic heart failure; the nurse’s care. Eur J Heart Fail 2001; 3: 449–456.

24. Lukaski HC, Kyle UG and Kondrup J. Assessment of adult malnutrition and prognosis with bioelectrical impedance analysis: phase angle and impedance ratio. Curr Opin Clin Nutr Metab Care 2017; 20: 330–339.
25. Peng F, Sun L, Chen T, et al. Albumin-globulin ratio and mortality in patients on peritoneal dialysis: a retrospective study. *BMC Nephrol* 2020; 21: 51.

26. Chen J, Zhou Y, Xu Y, et al. Low pretreatment serum globulin may predict favorable prognosis for gastric cancer patients. *Tumour Biol* 2016; 37: 3905–3911.

27. Stohl W, Kenol B, Kelly AJ, et al. Elevated serum globulin gap as a highly reliable marker of elevated erythrocyte sedimentation rate in patients with systemic rheumatic diseases. *Semin Arthritis Rheum* 2019; 49: 485–492.

28. Yoshino Y, Taguchi A, Shimizuguchi T, et al. A low albumin to globulin ratio with a high serum globulin level is a prognostic marker for poor survival in cervical cancer patients treated with radiation based therapy. *Int J Gynecol Cancer* 2019; 29: 17–22.

29. Xuan Q, Yang Y, Ji H, et al. Combination of the preoperative albumin to globulin ratio and neutrophil to lymphocyte ratio as a novel prognostic factor in patients with triple negative breast cancer. *Cancer Manag Res* 2019; 11: 5125–5131.

30. Xu WZ, Li F, Xu ZK, et al. Preoperative albumin-to-globulin ratio and prognostic nutrition index predict prognosis for glioblastoma. *Onco Targets Ther* 2017; 10: 725–733.

31. Bozkaya Y, Erdem GU, Demirci NS, et al. Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients. *Curr Med Res Opin* 2019; 35: 275–282.

32. He X, Guo S, Chen D, et al. Preoperative Albumin to Globulin Ratio (AGR) as Prognostic Factor in Renal Cell Carcinoma. *J Cancer* 2017; 8: 258–265.

33. Li K, Wang R, Huang S, et al. Prognostic Nomogram for Overall Survival in Extranodal Natural Killer/T-Cell Lymphoma Patients. *Clin Lymphoma Myeloma Leuk* 2018; 18: e537–e543.

34. Wang A, Chen G, Cao Y, et al. Estimated Glomerular Filtration Rate, Proteinuria, and Risk of Cardiovascular Diseases and All-cause Mortality in Diabetic Population: a Community-based Cohort Study. *Sci Rep* 2017; 7: 17948.